Quantum Genomics

France - ParisBiotechnology1 H-1B visas (FY2023)

Focus: Quantum Genomics is a Paris-based biotechnology company focused on small molecule development in neurology and respiratory therapeutic areas. The company operates a dual portfolio of generic/ANDA products and early-stage pipeline programs.

Neurology Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Quantum Genomics

AI assessmentNot Hiring

No open roles listed right now. Follow Quantum Genomics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

CLORAZEPATE DIPOTASSIUM

Anxiety disorders

$1M Part D

Pre-Launch

Lead revenue driver (54% of portfolio) but pre-launch status and modest Part D spend suggest early commercialization phase.

Help build intelligence for Quantum Genomics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead a Phase 3 program (Firibastat for hypertension) with near-term regulatory catalysts and clinical validation
Access to early-stage innovation across cardiovascular (QGC001, Ramipril) with unmet medical need in heart failure
European biotech base with small molecule expertise in high-prevalence indications (HTN, anxiety, depression)

Watch Out For

Zero active job openings signal potential stagnation or hiring freeze despite pipeline activity
Heavy revenue dependency on a single pre-launch generic (54% concentration in Clorazepate) with minimal monetization clarity
Sparse published data, no disclosed financials, and minimal transparency on company scale and burn rate create execution uncertainty

Generated by Claude from Quantum Genomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

RESTORIL

Insomnia

$984K Part D

Established NDA product with incoming patent cliff; Part D revenue declining and near loss of exclusivity.

TRIALODINE

Major Depressive Disorder

Pre-Launch

Pre-launch ANDA in depression market with SSRI/5HT2 antagonist mechanism; revenue potential unclear.